Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018107 · ClinicalTrials.gov registry record · NA
PET/CT-Assessment of Liver Tumor Ablation
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT02018107 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 33 participants.
The verdict
NCT02018107, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
In this research study, the investigators are evaluating whether ammonia PET scans or FDG PET perfusion scans are more useful in helping radiologists determine whether liver tumors were successfully destroyed by the heating or freezing procedures (ablations) than other scans currently available to radiologists, such as CT scans and MRI scans. The currently available scan (usually a CT scan with contrast dye) is not always effective in showing how completely the tumor has been destroyed. The ammonia PET scan is a different way of looking at how much tumor has been destroyed. This study will compare the standard scan (CT scan) with the ammonia PET scan.
Interventions
- DIAGNOSTIC_TEST PET scan
- DIAGNOSTIC_TEST N-13 ammonia or F-18 fluorodeoxyglucose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-01 |
| Est. Completion | 2019-02-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02018107
The ClinicalTrials.gov registry entry for NCT02018107 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET scan is the first listed.
NCT02018107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02018107 about?
NCT02018107 is a clinical study titled "PET/CT-Assessment of Liver Tumor Ablation". In this research study, the investigators are evaluating whether ammonia PET scans or FDG PET perfusion scans are more useful in helping radiologists determine whether liver tumors were successfully destroyed by the heating or freezing procedures (ablations) than other scans currently available to r...
What is the current status of trial NCT02018107?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2014-01. Estimated completion is 2019-02-16.
What interventions are being tested in trial NCT02018107?
The interventions under investigation include: PET scan (DIAGNOSTIC_TEST), N-13 ammonia or F-18 fluorodeoxyglucose (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02018107?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.